The start of the fall term in the U.S. Court of Appeals for the D.C. Circuit wasn’t a particularly pleasant one for the U.S. Justice Department, which found itself last week taking a barrage of questions over whether the government left the court in the dark about a controversial enforcement action against a national pharmaceutical chain.
The appeals court, which resumed hearing oral arguments on September 10 after a summer break, questioned DOJ’s stance in a closely watched dispute between CVS Caremark Corp. and the U.S. Drug Enforcement Administration over licenses to sell controlled substances at two retail stores in Florida.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
